Smith J S, Kiloh L G
J Neurol Neurosurg Psychiatry. 1979 Jun;42(6):576-9. doi: 10.1136/jnnp.42.6.576.
Using a blind evaluation of cinematographic films of patients suffering from tardive dyskinesia we found that thiopropazate hydrochloride in a dosage up to 30 mg daily was effective in reducing the severity of the dyskinesia in most patients. The overall improvement in the group of patients studied was not significant after one or three months of therapy but was significant after six months of treatment. The administration of thiopropazate hydrochloride over a six month period did not appear to aggravate the underlying pathophysiology so that the drug could be considered likely to be safe for long-term use. The anticholinergic antiparkinsonism agent benztropine mesylate aggravated the dyskinesia to a significant degree.
通过对迟发性运动障碍患者的电影胶片进行盲法评估，我们发现，每日剂量高达30毫克的盐酸硫丙嗪在减轻大多数患者运动障碍的严重程度方面是有效的。在治疗1个月或3个月后，所研究患者组的总体改善并不显著，但在治疗6个月后显著。在6个月期间给予盐酸硫丙嗪似乎并未加重潜在的病理生理学状况，因此该药物可被认为可能长期使用是安全的。抗胆碱能抗帕金森病药物甲磺酸苯扎托品在很大程度上加重了运动障碍。
